Literature DB >> 21277404

Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models.

Workineh Torben1, Gul Ahmad, Weidong Zhang, Afzal A Siddiqui.   

Abstract

Schistosomiasis is an important public health concern in more than 76 developing countries. Advent of an anti-schistosome vaccine would undoubtedly add to the existing control measures and may eventually help in the elimination of this disease. In the present study we have attempted to dissect the role(s) of antibodies in Sm-p80 mediated protection by intravenously transferring pooled sera from mice immunized with Sm-p80-pcDNA3 or purified IgG from baboons immunized with Sm-p80-pcDNA3, into naïve C57BL/6 mice, respectively, prior to challenge with cercariae. The passive transfer of antibodies from protected mice (homologous transfers) as well as transfer of total IgG from baboons (heterologous transfers), into naïve mice showed statistically significant reductions in worm burden and in the number of eggs in the tissues. Immunizations of antibody knockout mice (μMt-/-; B10.129S2 (B6)-Igh-6(tm1Cgn)/J) with recombinant Sm-p80 in the presence of CpG-motif oligodeoxynucleotides as an adjuvant, resulted in substantial reduction of Sm-p80-mediated protection, compared to C57BL/6 (normal) control group of mice. Down regulation of cytokines that have important effects on B cell proliferation as well as the recovery of higher number of parasites in antibody knockout indicated a significant role(s) of antibodies in Sm-p80-mediated protection against Schistosoma mansoni in mice. In toto, these studies appear to suggest that antibodies play a significant role in Sm-p80 mediated protection.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277404      PMCID: PMC3063403          DOI: 10.1016/j.vaccine.2011.01.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.

Authors:  Hatem Tallima; Mona Montash; Pavel Veprek; Jiri Velek; Jan Jezek; Rashika El Ridi
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Experimental models of immunization against schistosomes: lessons for vaccine development.

Authors:  S L James
Journal:  Immunol Invest       Date:  1992-08       Impact factor: 3.657

3.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

4.  Passive transfer with serum and IgG antibodies of irradiated cercaria-induced resistance against Schistosoma mansoni in mice.

Authors:  B L Mangold; D A Dean
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

5.  Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni.

Authors:  B W Young; R B Podesta
Journal:  J Parasitol       Date:  1986-10       Impact factor: 1.276

6.  Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation.

Authors:  Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Janet Pompa; Rachael M Villalovos; Michelle Paz
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

7.  Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Zahid Noor; Afzal A Siddiqui
Journal:  Int J Infect Dis       Date:  2010-07-13       Impact factor: 3.623

8.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

9.  Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo.

Authors:  E J Pearce; S L James
Journal:  Parasite Immunol       Date:  1986-09       Impact factor: 2.280

10.  Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.

Authors:  G Ahmad; W Torben; W Zhang; M Wyatt; A A Siddiqui
Journal:  Parasite Immunol       Date:  2009-03       Impact factor: 2.280

View more
  18 in total

1.  Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy.

Authors:  Weidong Zhang; Adebayo J Molehin; Juan U Rojo; Justin Sudduth; Pramodh K Ganapathy; Eunjee Kim; Arif J Siddiqui; Jasmin Freeborn; Souad R Sennoune; Jordan May; Samra Lazarus; Catherine Nguyen; Whitni K Redman; Gul Ahmad; Workineh Torben; Souvik Karmakar; Loc Le; Kameswara R Kottapalli; Pratibha Kottapalli; Roman F Wolf; James F Papin; David Carey; Sean A Gray; Jenn D Bergthold; Raymond T Damian; Bryan T Mayer; Florian Marks; Steven G Reed; Darrick Carter; Afzal A Siddiqui
Journal:  Ann N Y Acad Sci       Date:  2018-08       Impact factor: 5.691

2.  Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Afzal Ahrorov; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Pauline N M Mwinzi; Lisa Ganley-Leal; Ronald C Kennedy; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 3.  Schistosomiasis vaccines.

Authors:  Afzal A Siddiqui; Bilal A Siddiqui; Lisa Ganley-Leal
Journal:  Hum Vaccin       Date:  2011-11-01

4.  In vivo schistosomicidal activity of three novels 8-hydroxyquinoline derivatives against adult and immature worms of Schistosoma mansoni.

Authors:  Gamal Allam; Ahmad F Eweas; Abdelaziz S A Abuelsaad
Journal:  Parasitol Res       Date:  2013-06-22       Impact factor: 2.289

5.  Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.

Authors:  Workineh Torben; Gul Ahmad; Weidong Zhang; Stewart Nash; Loc Le; Souvik Karmakar; Afzal A Siddiqui
Journal:  Vaccine       Date:  2012-09-20       Impact factor: 3.641

6.  Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.

Authors:  Weidong Zhang; Gul Ahmad; Loc Le; Juan U Rojo; Souvik Karmakar; Kory A Tillery; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2014-04-12       Impact factor: 2.289

7.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289

8.  Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Mayeen U Alam; Richard Winn; Workineh Torben; Loc Le; Kory A Tillery; Afzal A Siddiqui
Journal:  Hum Vaccin Immunother       Date:  2013-12-27       Impact factor: 3.452

Review 9.  Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.

Authors:  Rachel Stephenson; Hong You; Donald P McManus; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2014-09-02

Review 10.  Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review.

Authors:  Rashika El Ridi; Hatem Tallima
Journal:  J Adv Res       Date:  2014-10-20       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.